News Archive

2021

September

Media Release / Sep 17, 2021

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)

Read More

August

Media Release / Aug 31, 2021

Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)

Read More
Media Release / Aug 17, 2021

Novartis announces positive results from Phase III trials of BEOVU® in diabetic macular edema, including dosing intervals up to 16 weeks

Read More

July

Media Release / Jul 20, 2021

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Read More

June

Media Release / Jun 04, 2021

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Read More
Media Release / Jun 04, 2021

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Read More
Media Release / Jun 03, 2021

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Read More
Media Release / Jun 02, 2021

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Read More
Media Release / Jun 02, 2021

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Read More
Media Release / Jun 01, 2021

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Read More

Related Links